Relugolix
Product Specifications
CAS Number
737789-87-6
Target
GNRH Receptor
Related Pathways
GPCR/G Protein
Purity
0.9997
Bioactivity
Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH) ) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH) . In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
Smiles
CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C
Molecular Formula
C29H27F2N7O5S
Molecular Weight
623.63
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Product Datasheet
https://www.targetmol.com/attachment/DataSheet/08D7B727-E678-4C67-93A0-42C152D669B2/T3630
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
